- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02581826
Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Premature Ejaculation (PE) is characterized as the most common sexual dysfunction in men with a prevalence of 21-33%. Based on the main theories about the pathophysiology of Premature Ejaculation (PE), the most commonly prescribed medications are topical anesthetics and serotonin-specific reuptake inhibitors (SSRIs). It has been reported that the abnormal ejaculation of semen is a typical but rather infrequent side effect of some α1-adrenoceptor antagonists. Silodosin had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.
Patients suitable for inclusion in the baseline period were those who (as part of the Premature Ejaculation Diagnostic Tool (PEDT) questionnaire) rated their perceived control over ejaculation as 'moderately difficult', 'very difficult' or 'extremely difficult', and the other four items as 'about half the time', 'more than half the time' or 'almost always or always'. Patients completed the Index of Premature Ejaculation (IPE) and Premature Ejaculation Profile (PEP) questionnaires, and rated the quality of their orgasm in response to the question: 'In general, how do you rate the orgasm you experience during sexual intercourse?' on a 5-point scale ('very poor', 'poor', 'satisfactory', 'good', 'very good'). Patients with a baseline Intravaginal Ejaculation Latency Time (IELT) of 2 minutes or less, as measured by a partner-held stopwatch, for at least two of the first three sexual encounters were eligible for randomization into the double-blind phase. In total of 40 eligible patients were randomized to receive double-blind treatment with 4 mg Silodosin or matched placebo for 3 months. One dose was to be taken 2 hours before anticipated sexual intercourse, and only one dose was allowed per 24-h period. Ejaculation-delaying techniques and behavioural therapy were to be avoided. Couples were instructed to attempt sexual intercourse four or more times per month during the 12-week treatment period (minimum of 24 h between doses of medication). During each sexual encounter, the Intravaginal Ejaculation Latency Time (IELT) was measured and recorded, together with efficacy and tolerability data. Ejaculation occurring before penetration was assigned an Intravaginal Ejaculation Latency Time (IELT) of 0 minute. The time noted on the stopwatch at this point was recorded as the duration of sexual intercourse until ejaculation or withdrawal. Patients returned to the clinic at 14-21 days intervals (visits 1, 2, 3, 4, 5 and 6) at which the Index of Premature Ejaculation (IPE) and Premature Ejaculation Profile (PEP) questionnaires were completed. Also, at visit 3 and 6 patients had a safety evaluation and rated the quality of their orgasms. Patients' satisfaction for the treatment was evaluated by Clinical Global Impression of Change (CGIC) in Premature Ejaculation (PE).
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Cheng-Hsing Hsieh, MD
- Phone Number: 2240 +886-6628-9779
- Email: kevinchhsieh@tzuchi.com.tw
Study Contact Backup
- Name: Jih-Rong Yang, MSc
- Phone Number: 2240 +886-6628-9779
- Email: xdb05251@tzuchi.com.tw
Study Locations
-
-
Xindian
-
Taipei, Xindian, Taiwan, 23142
- Recruiting
- Cheng-Hsing Hsieh
-
Contact:
- Jih-Rong Yang, MSc
- Phone Number: 2240 +886-6628-9779
- Email: xdb05251@tzuchi.com.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Premature Ejaculation (PE) diagnosed by Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) criteria.
- Stable heterosexual, monogamous relationships more than 3 months.
- Age of 20 years or order.
- Written informed consent.
Exclusion Criteria:
- α1-adrenoceptor antagonists within 4 weeks.
- Erectile dysfunction (ED) defined by an Index of Erectile Function (IIEF-5) score < 21.
- History of physical or psychological disorder (patient or partner).
- Patient need to adjust dosage during the screening and treatment period, including tricyclic antidepressants, monoamine oxidase inhibitors or selective serotonin reuptake inhibitors (SSRIs).
- Antidepressant therapy, local anaesthetic spray, intracavernosal injection or psychotherapy within 4 weeks.
- History of alcohol or drug abuse.
- Pregnant partners.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Silodosin
|
α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens.
Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%.
It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE).
A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission.
It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
Other Names:
|
Placebo Comparator: Placebo
|
No column specified.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Intravaginal Ejaculatory Latency Time (IELT)
Time Frame: up to 12 weeks
|
up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Erectile function domain of the International Index of Erectile Function (IIEF)
Time Frame: Baseline
|
Baseline
|
Premature Ejaculation Diagnostic Tool (PEDT)
Time Frame: Baseline
|
Baseline
|
Index of Premature Ejaculation (IPE)
Time Frame: up to 12 weeks
|
up to 12 weeks
|
Premature Ejaculation Profile (PEP)
Time Frame: up to 12 weeks
|
up to 12 weeks
|
Clinical Global Impression of Change (CGIC)
Time Frame: up to 12 weeks
|
up to 12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Cheng-Hsing Hsieh, MD, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pregnancy Complications
- Obstetric Labor Complications
- Sexual Dysfunctions, Psychological
- Obstetric Labor, Premature
- Sexual Dysfunction, Physiological
- Premature Birth
- Premature Ejaculation
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Silodosin
Other Study ID Numbers
- 01-X15-058
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Premature Ejaculation
-
Janssen Research & Development, LLCCompletedSexual Dysfunction, Physiological | EjaculationGermany, Spain, Portugal, Finland, Sweden, Austria
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedSexual Dysfunction | Ejaculation
-
Sohag UniversityCompletedVitamin D, Vitamin B12 and Folic Acid Among Patients With Premature EjaculationEgypt
-
PfizerCompletedEjaculationUnited States
-
Alza Corporation, DE, USACompleted
-
PfizerCompletedEjaculationUnited States, Australia, Canada, United Kingdom
-
PfizerCompletedEjaculationItaly, Spain, Australia, Austria, Canada, Czech Republic, France, Germany, Israel, Norway, Poland, Sweden, Turkey, Netherlands
-
Alza Corporation, DE, USACompleted
-
Plethora Solutions LtdCompleted
-
Virility Medical Ltd.Sintesi Research SrlCompleted
Clinical Trials on Silodosin
-
Watson PharmaceuticalsCompletedAbacterial Chronic Prostatitis/Chronic Pelvic Pain SyndromeUnited States
-
Taiho Oncology, Inc.RecruitingAdvanced Cholangiocarcinoma | FGFR2 Fusions | Gene RearrangementUnited States, Korea, Republic of, Spain, Japan, Portugal, Italy, China, Argentina, Brazil, Poland, Australia
-
Taiho Oncology, Inc.Approved for marketingAdvanced CholangiocarcinomaUnited States
-
JW PharmaceuticalCompletedNeurogenic Bladder | Voiding DysfunctionKorea, Republic of
-
Watson PharmaceuticalsCompletedUrolithiasis | Ureteral Calculi | Kidney StonesUnited States
-
Xintian PharmaceuticalRecruitingBenign Prostatic Hyperplasia With Lower Urinary Tract SymptomsChina
-
Getz PharmaNot yet recruitingUreteric Stone of Lower Third of Ureter
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Watson PharmaceuticalsCompletedProstatic Hyperplasia | NocturiaUnited States
-
Albert Einstein Healthcare NetworkWithdrawn